Clinical Trial Update: Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update examining changes in weight, body composition, and metabolic parameters after discontinuation of dolutegravir or tenofovir dispr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• HIV Lipodystrophy
• Obesity
• Osteoporosis
• Renal Insufficiency
• Weight Gain

Drugs mentioned

• Dolutegravir (dolutegravir)
• Tenofovir disoproxil (Tenofovir disoproxil)

Snippet

Sponsor: Thomas Benfield | Conditions: Hiv, HIV Infections | Phase 4 | Status: UNKNOWN